ADLIN Science × Eurofins Genomics : from sample to interpretation

ADLIN Science and Eurofins Genomics partner to facilitate and accelerate the use of genomic data

‍

Ebersberg, Germany, 2nd June 2026 – Genomic data is growing faster than most teams can handle. Eurofins Genomics and ADLIN Science have joined forces to deliver an integrated, reproducible solution covering every step from biological sample to actionable insight.

‍

One ambition: Making genomic data truly actionable

By combining their complementary expertise, the two companies offer their clients an unique and consistent workflow covering the entire value chain, from data generation to its interpretation, while addressing key challenges such as reproducibility and interoperability:

- Eurofins Genomics, a leading genomics provider, manages data production, from sample handling to sequencing, leveraging its industrial-scale capabilities.

- ADLIN Science provides integrated software solutions to analyze, structure, and enhance the value of this data, notably by integrating multiple data types (multi-omics) and offering advanced exploration tools.

‍

« This partnership between two European companies is built on a strong conviction: the value of genomics lies not only in data generation, but in the ability to structure, analyze, and interpret it within its scientific context. By combining our expertise with that of Eurofins Genomics, we offer an integrated approach that enables a seamless and reproducible journey from sample to interpretation, across Europe.»

Paul Rinaudo, CEO of ADLIN Science

For Eurofins Genomics, this partnership represents a strategic step in delivering end-to-end genomic solutions to its clients. By integrating ADLIN Science's data structuring and analysis capabilities into its sequencing workflow, Eurofins Genomics strengthens its ability to support research and industrial teams throughout the entire data lifecycle — from sample to actionable insight.

‍

Accelerating applications in research and industry

The joint offering addresses a wide range of use cases in both research and industry with a initial focus on Pharma and clinical studies and including:

• biomarker identification and validation,

• translational research and

• clinical programs,

• multi-omics data analysis,

• bioproduction and

• genetic stability monitoring,

• as well as applications in dermo cosmetics and life sciences.

‍

It notably enables faster access to actionable results, improved reproducibility of analyses, better structuring of data flows from sequencing to interpretation, and increased autonomy for scientific teams. These benefits align with a fully integrated value chain approach.

‍

A structured and evolving collaboration

The partnership is built on a structured framework that includes joint commercial promotion and coordinated business development efforts and close technical collaboration ensuring system interoperability.

‍

‍

‍